Sorrento Therapeutics Inc (SRNE)

[Couch]

$1.80 Post Market!!!

Here is the Prospectus! I believe it states somewhere that SRNE's CEO gets to purchase shares at $2 - which he did today..........see the Form 4. It looks like he may have purchased 100,000 shares today at $2.

Please let me know what others see here!!

https://www.streetinsider.com/SEC+Filings/Form+424B5+Sorrento+Therapeutics%2C+/12780358.html

http://ih.advfn.com/p.php?pid=nmona&article=74373540&symbol=SRNE

We are offering 23,625,084 shares of our common stock in this offering.

Our common stock is listed on the NASDAQ Capital Market under the symbol “SRNE.” On April 11, 2017, the last reported sale price of our common stock on the NASDAQ Capital Market was $2.95 per share.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-8 of this prospectus supplement and under similar headings in the documents incorporated by reference into this prospectus supplement for a discussion of certain risks you should consider before investing in shares of our common stock.

Per Share Total
Public offering price $ 2.00 $ 47,250,168.00
Underwriting discounts and commissions(1) $ 0.1429 $ 3,376,024.50
Proceeds to us before expenses $ 1.8571 $ 43,874,143.50


(1) We have agreed to reimburse the representative of the underwriters for certain of its expenses. See “Underwriting” for a description of the compensation to be received by the underwriters.
We have granted the underwriters a 30-day option to purchase up to 3,543,763 additional shares of common stock from us at the public offering price, less underwriting discounts and commissions.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the common stock to the investors in book-entry form through the facilities of The Depository Trust Company on or about April 19, 2017.


Lead Book-Running Manager
Cantor Fitzgerald & Co. Joint Book-Running Manager
FBR Capital Markets & Co.


Co-Lead Managers
Oppenheimer & Co. Aegis Capital Corp.


Co-Managers
Joseph Gunnar & Co. Rodman & Renshaw Roth Capital Partners

The date of this prospectus supplement is April 13, 2017